PF-00299804

DRUG15 trials

Sponsors

Pfizer, NCIC Clinical Trials Group, Massachusetts General Hospital, University Health Network, Toronto, Yonsei University

Conditions

Advanced Malignant Solid TumorsCarcinoma, Non Small Cell LungCarcinoma, Non-Small CellGBMGlioblastomaGlioblastoma MultiformeHead Neck Cancer Squamous Cell MetastaticHead Neck Cancer Squamous Cell Recurrent

Phase 1

Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

CompletedNCT00225121

PfizerNeoplasms

Start: 2005-10-11End: 2010-09-23Updated: 2018-12-21

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

CompletedNCT00728390

PfizerCarcinoma, Non-Small Cell, Neoplasm Metastasis

Start: 2008-12-15End: 2013-01-29Updated: 2024-04-22

A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients

CompletedNCT00728468

PfizerAdvanced Malignant Solid Tumors

Start: 2008-09-30End: 2014-07-31Updated: 2017-08-02

A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

CompletedNCT00783328

PfizerNeoplasms

Start: 2008-11-30End: 2011-03-31Updated: 2011-06-27

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

TerminatedNCT00971191

PfizerNon-Small Cell Lung Cancer (NSCLC)

Start: 2010-02-28End: 2012-05-31Updated: 2012-06-22

Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

CompletedNCT01116843

University Health Network, TorontoOral Cavity Cancer

Start: 2010-05-31End: 2014-02-28Updated: 2015-07-10

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

CompletedNCT01121575

PfizerNon Small Cell Lung Cancer

Start: 2010-08-31End: 2014-02-28Updated: 2015-10-28

Phase 2

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

CompletedNCT00548093

PfizerCarcinoma, Non Small Cell Lung

Start: 2008-04-29End: 2012-06-11Updated: 2019-05-21

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

CompletedNCT00553254

PfizerCarcinoma, Non Small Cell Lung

Start: 2008-02-05End: 2014-07-17Updated: 2020-10-19

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

CompletedNCT00769067

PfizerNon-small Cell Lung Cancer

Start: 2008-11-30End: 2014-08-31Updated: 2015-10-07

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

CompletedNCT00768664

PfizerHead and Neck Neoplasms

Start: 2008-11-04End: 2012-04-18Updated: 2021-02-09

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

CompletedNCT01112527

Massachusetts General HospitalGBM, Glioblastoma, Glioblastoma Multiforme

Start: 2010-04-30End: 2015-09-30Updated: 2018-08-16

PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

CompletedNCT01449201

Yonsei UniversityHead Neck Cancer Squamous Cell Metastatic, Head Neck Cancer Squamous Cell Recurrent

Start: 2011-10-31End: 2014-03-31Updated: 2014-09-30

Phase 3

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

CompletedNCT01000025

NCIC Clinical Trials GroupLung Cancer

Start: 2009-12-23End: 2015-11-27Updated: 2023-08-22

Unknown Phase

A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma

CompletedNCT01484847

University Health Network, TorontoHead and Neck Squamous Cell Carcinoma

Start: 2011-12-31End: 2015-07-31Updated: 2015-07-10

Related Papers

OMRT-2. Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma

Neuro-Oncology Advances2021-07-01

Abstract 456: Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma

Cancer Research2021-07-01

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

2016-01-1340 citations

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials

QUT ePrints (Queensland University of Technology)2016-01-01

Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).

2015-05-058 citations

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

2014-10-1597 citations

The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck.

2014-07-2359 citations

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

Journal of Clinical Oncology2014-05-2014 citations

Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.

Journal of Clinical Oncology2014-05-205 citations

Pharmacokinetic (PK) assessment of dacomitinib (D) in patients with locoregionally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through gastrostomy feeding tube (GT).

Journal of Clinical Oncology2014-05-20

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.

2014-02-0598 citations

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.

2012-01-1748 citations